In non-diabetic STEMI patients, adiponectin appears to reflect not only chronic metabolic risk but also acute insulin-resistance states and endothelial dysfunction that influence reperfusion efficacy and post-infarction remodeling. This evidence concerns the gene ADIPOQ and Insulin resistance.